Tag: $SpringWorks Therapeutics

Germany’s Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Merck KGaA (MRCG.DE),  has struck a deal to buy U.S. biotech company SpringWorks Therapeutics (SWTX.O),  for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.